Core Points - A securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for alleged material misstatements and omissions affecting investors [1][3] - The lawsuit pertains to the period from September 17, 2024, to May 26, 2025, during which investors may seek compensation [2] - The lawsuit claims that Rocket Pharmaceuticals failed to disclose significant safety-related updates regarding its RP-A501 clinical trial, leading to a fatal adverse event and subsequent FDA clinical hold [3] Company Overview - Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, and specializes in gene therapies for rare and life-threatening diseases [2] - Following the public confirmation of the trial hold and patient death on May 28, 2025, Rocket Pharmaceuticals' stock price plummeted from $6.27 to $2.33 [3]

Core Points - A securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for alleged material misstatements and omissions affecting investors [1][3] - The lawsuit pertains to the period from September 17, 2024, to May 26, 2025, during which investors may seek compensation [2] - The lawsuit claims that Rocket Pharmaceuticals failed to disclose significant safety-related updates regarding its RP-A501 clinical trial, leading to a fatal adverse event and subsequent FDA clinical hold [3] Company Information - Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, and specializes in gene therapies for rare and life-threatening diseases [2] - Following the public confirmation of the trial hold and patient death on May 28, 2025, Rocket Pharmaceuticals' stock price plummeted from $6.27 to $2.33 [3]

Core Viewpoint - Berger Montague PC is investigating claims against Sable Offshore Corp. following a class action lawsuit alleging misrepresentation of oil production status [1][3] Group 1: Lawsuit Details - The class action lawsuit claims that Sable misrepresented that oil production off California's coast had resumed, which was not the case [3] - The lawsuit covers investors who purchased Sable securities between May 19, 2025, and June 3, 2025, including those involved in the May 2025 secondary offering [2] - Following the revelation of the truth regarding Sable's operations, the company's shares declined, resulting in investor losses [3] Group 2: Company Background - Sable Offshore Corp. is an offshore oil and gas operations company headquartered in Houston, Texas [1] - Berger Montague has been involved in securities class action litigation since 1970 and has represented both individual and institutional investors [4]

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities during the specified Class Period [1][2]. Company Overview - RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery [2]. Legal Allegations - The lawsuit alleges that RxSight failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz attributed the decline to adoption challenges [4]. - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

Core Viewpoint - Berger Montague PC is investigating Rocket Pharmaceuticals for potential violations of federal securities laws related to the RP-A501 trial, which allegedly concealed safety concerns leading to significant investor losses [1][2]. Company Overview - Rocket Pharmaceuticals is based in Cranbury, New Jersey, focusing on research and clinical programs in genetic medicine [2]. - The company introduced a new immunomodulatory agent into the RP-A501 protocol without disclosing this information to shareholders, which preceded a fatal adverse event [2]. Stock Performance - Following the announcement of an FDA clinical hold, Rocket Pharmaceuticals' stock price declined nearly 37% over two trading days [2]. Legal Proceedings - A class action has been filed for individuals who purchased Rocket Pharmaceuticals securities from September 17, 2024, to May 26, 2025, with a deadline to file for lead plaintiff set for August 11, 2025 [3].

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities between November 7, 2024, and July 8, 2025 [1][2] Company Overview - RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery [2] Legal Allegations - The lawsuit alleges that RxSight failed to disclose: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3] 2. Overstated demand for RxSight's products [3] 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3] Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance [4] - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4]

Core Viewpoint - Berger Montague is investigating potential securities fraud claims against Hims & Hers Health Inc. for making false or misleading statements to investors during the Class Period from April 29, 2025, to June 22, 2025 [1][2] Securities Fraud Investigation Details - On June 23, 2025, Hims & Hers shares fell over 34% after Novo Nordisk terminated its partnership due to unauthorized marketing and sale of compounded semaglutide drugs [2] - A complaint has been filed alleging material misstatements and omissions in violation of federal securities laws [2] Deadline to Act - Investors have until August 25, 2025, to seek appointment as lead plaintiff in the class action lawsuit [3] - Lead plaintiffs will help direct the case and advocate on behalf of other harmed investors [3]

Core Viewpoint - Berger Montague is investigating potential securities fraud claims against Petco Health and Wellness Company, following a federal securities class action lawsuit related to misleading statements about its pandemic-driven growth and product strategy [1][2]. Summary by Relevant Sections Allegations of Misleading Statements - The complaint alleges that Petco made false and misleading statements regarding the sustainability of its pandemic-driven growth and premium product strategy, which led to a significant decline in its stock price, including a drop of over 20% on August 24, 2023 [2]. Impact on Stock Price and Investor Confidence - The lawsuit indicates that Petco's stock experienced substantial losses following financial disclosures and executive departures during the Class Period from January 14, 2021, to June 5, 2025 [2][3]. - The company's efforts to adjust its product mix by introducing lower-cost pet food options contradicted prior public statements, further undermining investor confidence [3]. Leadership Changes and Earnings Guidance - Multiple leadership changes and continued downward revisions to earnings guidance highlighted the severity of Petco's challenges, negatively impacting investor sentiment [3].

Group 1 - A securities fraud investigation has been initiated into Hims & Hers Health Inc. regarding potential violations of the Securities Exchange Act of 1934, focusing on misleading information about regulatory compliance and business operations [1] - Following the termination of a collaboration with Novo Nordisk on June 23, 2025, Hims & Hers' stock experienced a decline of over 34% [2] - A class action lawsuit has been filed against Hims & Hers, alleging the company failed to disclose risks associated with its compounded drug offerings during the Class Period from April 29, 2025, to June 22, 2025 [2]

Core Viewpoint - A securities class action lawsuit has been filed against Rocket Pharmaceuticals, alleging material misstatements and omissions that led to investor losses [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Rocket Pharmaceuticals stock between September 17, 2024, and May 26, 2025 [2]. - The lawsuit claims that Rocket Pharmaceuticals failed to disclose significant safety-related updates regarding its RP-A501 clinical trial, including the use of an immunomodulatory agent, prior to a fatal adverse event and subsequent FDA-imposed clinical hold [3]. - Following the public confirmation of the trial hold and patient death on May 28, 2025, Rocket Pharmaceuticals' shares plummeted from $6.27 to $2.33 [3]. Group 2: Company Overview - Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, and specializes in gene therapies for rare and life-threatening diseases [2].